Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies–A review

References

• Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Ann Rev Pathol 2013; 8:49-78; PMID:22934675; http://dx.doi.org/10.1146/annurev-pathol-020712-164030
   PubMed Web of Science ®Google Scholar
• Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991; 256:271-82; PMID:1722017; http://dx.doi.org/10.1016/0921-8734(91)90018-7
   PubMed Web of Science ®Google Scholar
• Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM, Samali A. Cellular longevity: role of apoptosis and replicative senescence. Biogerontology 2002; 3:195-206; PMID:12232501; http://dx.doi.org/10.1023/A:1016299812327
   PubMedGoogle Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21:305-34; PMID:12471050; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141110
   PubMed Web of Science ®Google Scholar
• Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 2013; 25:214-21; PMID:23298609; http://dx.doi.org/10.1016/j.coi.2012.12.003
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Chino T, Draves KE, Clark EA. Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol 2009; 86:933-40; PMID:19641036; http://dx.doi.org/10.1189/jlb.0708419
   PubMedGoogle Scholar
• Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5:1219-26; PMID:15549123; http://dx.doi.org/10.1038/ni1141
   PubMed Web of Science ®Google Scholar
• Abediankenari S, Yousefzadeh Y, Azadeh H, Vahedi M. Comparison of several maturation inducing factors in dendritic cell differentiation. Iran J Immunol 2010; 7:83-8; PMID:20574121
   PubMed Web of Science ®Google Scholar
• Granucci F, Zanoni I. The dendritic cell life cycle. Cell Cycle 2009; 8:3816-21; PMID:19887908; http://dx.doi.org/10.4161/cc.8.23.9998
   PubMed Web of Science ®Google Scholar
• Hou WS, Van Parijs L. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol 2004; 5:583-9; PMID:15133508; http://dx.doi.org/10.1038/ni1071
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/cncr.24429
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson D, Richards J, Conry RM, Miller D, Triesman J, Gailani F, Riley LB, Vena D, Hwu P. A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol Meeting Abstracts 2009; 27:CRA9011
   Google Scholar
• Flowers CR. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma. Expert Rev Vaccines 2007; 6:307-17; PMID:17542746; http://dx.doi.org/10.1586/14760584.6.3.307
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100:230-7; PMID:12070032; http://dx.doi.org/10.1182/blood.V100.1.230
   PubMed Web of Science ®Google Scholar
• Troy AJ, Davidson PJ, Atkinson CH, Hart DN. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J Urol 1999; 161:1962-7; PMID:10332481; http://dx.doi.org/10.1016/S0022-5347(05)68864-7
   PubMedGoogle Scholar
• Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3:483-90; PMID:9815709
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997; 15:144-53; PMID:9090791; http://dx.doi.org/10.1002/stem.150144
   PubMedGoogle Scholar
• Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159:4772-80; PMID:9366401
   PubMed Web of Science ®Google Scholar
• Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92:4150-66; PMID:9834220
   PubMed Web of Science ®Google Scholar
• Aalamian M, Tourkova IL, Chatta GS, Lilja H, Huland E, Huland H, Shurin GV, Shurin MR. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol 2003; 170:2026-30; PMID:14532846; http://dx.doi.org/10.1097/01.ju.0000091264.46134.b7
   PubMed Web of Science ®Google Scholar
• Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN, Lotze MT, Shurin MR. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer 2000; 83:506-13; PMID:10945499; http://dx.doi.org/10.1054/bjoc.2000.1289
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, Griffin GE, Taylor GP, Tough DF, Beverley PC et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology 2007; 121:258-65; PMID:17346281; http://dx.doi.org/10.1111/j.1365-2567.2007.02573.x
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10; PMID:18425107; http://dx.doi.org/10.1038/ni1582
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx.doi.org/10.1126/science.1198687
   PubMed Web of Science ®Google Scholar
• Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005; 26:221-6; PMID:15797513; http://dx.doi.org/10.1016/j.it.2005.02.007
   PubMed Web of Science ®Google Scholar
• Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004; 22:405-29; PMID:15032583; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104711
   PubMed Web of Science ®Google Scholar
• Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10:230-52; PMID:23604045; http://dx.doi.org/10.1038/cmi.2013.10
   PubMed Web of Science ®Google Scholar
• Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009; 266:154-81; PMID:19614820; http://dx.doi.org/10.1111/j.1365-2796.2009.02121.x
   PubMed Web of Science ®Google Scholar
• Jewett A, Tseng HC. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer 2011; 2:443-57; PMID:21850212; http://dx.doi.org/10.7150/jca.2.443
   PubMed Web of Science ®Google Scholar
• Thomas GR, Chen Z, Leukinova E, Van Waes C, Wen J. Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol Immunother 2004; 53:33-40; PMID:14551747; http://dx.doi.org/10.1007/s00262-003-0433-4
   PubMed Web of Science ®Google Scholar
• Jewett A, Cavalcanti M, Bonavida B. Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol 1997; 159:4815-22; PMID:9366406
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9:495-502; PMID:18425106; http://dx.doi.org/10.1038/ni1581
   PubMed Web of Science ®Google Scholar
• Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004; 64:215-25; PMID:15304001; http://dx.doi.org/10.1111/j.0001-2815.2004.00290.x
   PubMedGoogle Scholar
• Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-41; PMID:6176669; http://dx.doi.org/10.1084/jem.155.6.1823
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17:6287-97; PMID:21844012; http://dx.doi.org/10.1158/1078-0432.CCR-11-1347
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.2010.515582
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549
   PubMed Web of Science ®Google Scholar
• Min-Oo G, Kamimura Y, Hendricks DW, Nabekura T, Lanier LL. Natural killer cells: walking three paths down memory lane. Trends Immunol 2013; 34:251-8; PMID:23499559; http://dx.doi.org/10.1016/j.it.2013.02.005
   PubMedGoogle Scholar
• Carding SR, Egan PJ. Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002; 2:336-45; PMID:12033739; http://dx.doi.org/10.1038/nri797
   PubMed Web of Science ®Google Scholar
• Tough DF, Sprent J. Lifespan of gammadelta T cells. J Exp Med 1998; 187:357-65; PMID:9449716; http://dx.doi.org/10.1084/jem.187.3.357
   PubMedGoogle Scholar
• Anane LH, Edwards KM, Burns VE, Zanten JJCSVv, Drayson MT, Bosch JA. Phenotypic characterization of γδ T cells mobilized in response to acute psychological stress. Brain Behav Immun 2010; 24:608-14; PMID:20060888; http://dx.doi.org/10.1016/j.bbi.2010.01.002
   PubMedGoogle Scholar
• Eberl M, Engel R, Beck E, Jomaa H. Differentiation of human gamma-delta T cells towards distinct memory phenotypes. Cell Immunol 2002; 218:1-6; PMID:12470608; http://dx.doi.org/10.1016/S0008-8749(02)00519-1
   PubMed Web of Science ®Google Scholar
• Gomes AQ, Martins DS, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 2010; 70:10024-7; PMID:21159627; http://dx.doi.org/10.1158/0008-5472.CAN-10-3236
   PubMed Web of Science ®Google Scholar
• Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011; 105:778-86; PMID:21847128; http://dx.doi.org/10.1038/bjc.2011.293
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol 2013; 31:413-41; PMID:23298206; http://dx.doi.org/10.1146/annurev-immunol-032712-095951
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:591-9; PMID:9620680; http://dx.doi.org/10.1016/S1074-7613(00)80564-6
   PubMed Web of Science ®Google Scholar
• Surh CD, Sprent J. Homeostasis of Naive and Memory T Cells. Immunity 2008; 29:848-62; PMID:19100699; http://dx.doi.org/10.1016/j.immuni.2008.11.002
   PubMed Web of Science ®Google Scholar
• Wong P, Pamer EG. CD8 T cell responses to infectious pathogens. Annu Rev Immunol 2003; 21:29-70; PMID:12414723; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141114
   PubMed Web of Science ®Google Scholar
• Michelini RH, Doedens AL, Goldrath AW, Hedrick SM. Differentiation of CD8 memory T cells depends on Foxo1. J Exp Med 2013; 210:1189-200; PMID:23712431; http://dx.doi.org/10.1084/jem.20130392
   PubMed Web of Science ®Google Scholar
• Sprent J, Surh CD. T cell memory. Annu Rev Immunol 2002; 20:551-79; PMID:11861612; http://dx.doi.org/10.1146/annurev.immunol.20.100101.151926
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C et al. Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci 2009; 106:17469-74; PMID:19805141; http://dx.doi.org/10.1073/pnas.0907448106
   PubMed Web of Science ®Google Scholar
• Shafer-Weaver KA, Anderson MJ, Stagliano K, Malyguine A, Greenberg NM, Hurwitz AA. Cutting edge: tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 2009; 183:4848-52; PMID:19801511; http://dx.doi.org/10.4049/jimmunol.0900848
   PubMed Web of Science ®Google Scholar
• Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol 2012; 3:51; PMID:22566933; http://dx.doi.org/10.3389/fimmu.2012.00051
   PubMed Web of Science ®Google Scholar
• Shimabukuro-Vornhagen A, Draube A, Liebig TM, Rothe A, Kochanek M, von Bergwelt-Baildon MS. The immunosuppressive factors IL-10, TGF-beta, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res 2012; 31:47; PMID:22592077; http://dx.doi.org/10.1186/1756-9966-31-47
   PubMed Web of Science ®Google Scholar
• Wu R, Forget M-A, Chacon J, Bernatchez C, Haymaker C, Chen JQ, Hwu P, Radvanyi LG. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012; 18:160-75; PMID:22453018; http://dx.doi.org/10.1097/PPO.0b013e31824d4465
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013; 13:525-41; PMID:23880905; http://dx.doi.org/10.1038/nrc3565
   PubMed Web of Science ®Google Scholar
• Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. OncoImmunol 2013; 2:e25962; PMID:24327938; http://dx.doi.org/10.4161/onci.25962
   PubMedGoogle Scholar
• Hombach A, Heuser C, Marquardt T, Wieczarkowiecz A, Groneck V, Pohl C, Abken H. CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and fas-independent fashion. J Immunol 2001; 167:1090-6; PMID:11441120; http://dx.doi.org/10.4049/jimmunol.167.2.1090
   PubMedGoogle Scholar
• Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJN. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 2013; 21:638-47; PMID:23295945; http://dx.doi.org/10.1038/mt.2012.267
   PubMed Web of Science ®Google Scholar
• Mantripragada K, Reagan JL, Quesenberry PJ, Fast LD. Advances in cellular therapy for the treatment of leukemia. Discov Med 2014; 17:15-24; PMID:24411697
   PubMedGoogle Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9; PMID:16946036; http://dx.doi.org/10.1126/science.1129003
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Honemann D et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 2013; 21:2122-9; PMID:23831595; http://dx.doi.org/10.1038/mt.2013.154
   PubMed Web of Science ®Google Scholar
• Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ, Jr., Rosenberg SA, Hodes RJ. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007; 30:123-9; PMID:17198091; http://dx.doi.org/10.1097/01.cji.0000211321.07654.b8
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12:180-90; PMID:22343569; http://dx.doi.org/10.1038/nri3156
   PubMed Web of Science ®Google Scholar
• Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. Immune responses in interleukin-2-deficient mice. Science 1993; 262:1059-61; PMID:8235625; http://dx.doi.org/10.1126/science.8235625
   PubMedGoogle Scholar
• Bachmann MF, Wolint P, Walton S, Schwarz K, Oxenius A. Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections. Eur J Immunol 2007; 37:1502-12; PMID:17492805; http://dx.doi.org/10.1002/eji.200637023
   PubMedGoogle Scholar
• Cho JH, Boyman O, Kim HO, Hahm B, Rubinstein MP, Ramsey C, Kim DM, Surh CD, Sprent J. An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med 2007; 204:1787-801; PMID:17664294; http://dx.doi.org/10.1084/jem.20070740
   PubMedGoogle Scholar
• Kabelitz D, Kirchner H, Armerding D, Wagner H. Recombinant interleukin 2 rapidly augments human natural killer cell activity. Cell Immunol 1985; 93:38-45; PMID:2581709; http://dx.doi.org/10.1016/0008-8749(85)90386-7
   PubMed Web of Science ®Google Scholar
• Kabelitz D. Human gammadelta T lymphocytes for immunotherapeutic strategies against cancer. F1000 Med Rep 2010; 2; PMID:20948839
   PubMedGoogle Scholar
• Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99:16168-73; PMID:12427970; http://dx.doi.org/10.1073/pnas.242600099
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase III study of adoptive transfer of gammadelta T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 2011; 60:1075-84; PMID:21519826; http://dx.doi.org/10.1007/s00262-011-1021-7
   PubMed Web of Science ®Google Scholar
• Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11:1238-43; PMID:16227988; http://dx.doi.org/10.1038/nm1312
   PubMed Web of Science ®Google Scholar
• Clement JM, McDermott DF. The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7:E7-9; PMID:19692326; http://dx.doi.org/10.3816/CGC.2009.n.014
   PubMed Web of Science ®Google Scholar
• Gogas H, Polyzos A, Kirkwood J. Immunotherapy for advanced melanoma: fulfilling the promise. Cancer Treat Rev 2013; 39:879-85; PMID:23725878; http://dx.doi.org/10.1016/j.ctrv.2013.04.006
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998; 228:307-19; PMID:9742914; http://dx.doi.org/10.1097/00000658-199809000-00004
   PubMed Web of Science ®Google Scholar
• Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124:99-110; PMID:24292706; http://dx.doi.org/10.1172/JCI46266
   PubMed Web of Science ®Google Scholar
• von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181:1519-26; PMID:7699333; http://dx.doi.org/10.1084/jem.181.4.1519
   PubMed Web of Science ®Google Scholar
• Moore TA, von Freeden-Jeffry U, Murray R, Zlotnik A. Inhibition of gamma delta T cell development and early thymocyte maturation in IL-7 -- mice. J Immunol 1996; 157:2366-73; PMID:8805634
   PubMed Web of Science ®Google Scholar
• Chu YW, Memon SA, Sharrow SO, Hakim FT, Eckhaus M, Lucas PJ, Gress RE. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004; 104:1110-9; PMID:15130942; http://dx.doi.org/10.1182/blood-2003-10-3635
   PubMed Web of Science ®Google Scholar
• Fry TJ, Moniuszko M, Creekmore S, Donohue SJ, Douek DC, Giardina S, Hecht TT, Hill BJ, Komschlies K, Tomaszewski J et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101:2294-9; PMID:12411295; http://dx.doi.org/10.1182/blood-2002-07-2297
   PubMed Web of Science ®Google Scholar
• Storek J, Lu H, Kalina T, Kiem H. IL-7 improves reconstitution of CD4 T cells, including cytomegalovirus-specific CD4 T cells, in lymphopenic monkeys. J Allergy Clin Immunol 2004; 113:S50
   PubMed Web of Science ®Google Scholar
• Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005; 115:1177-87; PMID:15841203; http://dx.doi.org/10.1172/JCI200523134
   PubMed Web of Science ®Google Scholar
• Ruprecht CR, Gattorno M, Ferlito F, Gregorio A, Martini A, Lanzavecchia A, Sallusto F. Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med 2005; 201:1793-803; PMID:15939793; http://dx.doi.org/10.1084/jem.20050085
   PubMed Web of Science ®Google Scholar
• Li B, VanRoey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol 2007; 123:155-65; PMID:17320482; http://dx.doi.org/10.1016/j.clim.2007.01.002
   PubMedGoogle Scholar
• Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9; PMID:16699374; http://dx.doi.org/10.1097/01.cji.0000210386.55951.c2
   PubMed Web of Science ®Google Scholar
• Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701-14; PMID:18573906; http://dx.doi.org/10.1084/jem.20071681
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005; 202:907-12; PMID:16203864; http://dx.doi.org/10.1084/jem.20050732
   PubMed Web of Science ®Google Scholar
• Powell DJ, Jr., Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005; 105:241-50; PMID:15345595; http://dx.doi.org/10.1182/blood-2004-06-2482
   PubMed Web of Science ®Google Scholar
• Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-42; PMID:21508983; http://dx.doi.org/10.1038/nri2970
   PubMed Web of Science ®Google Scholar
• Michaud A, Dardari R, Charrier E, Cordeiro P, Herblot S, Duval M. IL-7 enhances survival of human CD56bright NK cells. J Immunother 2010; 33:382-90; PMID:20386468; http://dx.doi.org/10.1097/CJI.0b013e3181cd872d
   PubMed Web of Science ®Google Scholar
• Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, Godfrey DI. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 2007; 178:2827-34; PMID:17312126; http://dx.doi.org/10.4049/jimmunol.178.5.2827
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408:57-63; PMID:11081504; http://dx.doi.org/10.1038/35040504
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse HC, 3rd, Liu C, Schwartzberg PL, Leonard WJ. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298:1630-4; PMID:12446913; http://dx.doi.org/10.1126/science.1077002
   PubMed Web of Science ®Google Scholar
• Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005; 201:139-48; PMID:15630141; http://dx.doi.org/10.1084/jem.20041057
   PubMed Web of Science ®Google Scholar
• Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 2003; 171:608-15; PMID:12847225; http://dx.doi.org/10.4049/jimmunol.171.2.608
   PubMed Web of Science ®Google Scholar
• Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol 2009; 182:3423-31; PMID:19265120; http://dx.doi.org/10.4049/jimmunol.0803068
   PubMedGoogle Scholar
• Toomey JA, Gays F, Foster D, Brooks CG. Cytokine requirements for the growth and development of mouse NK cells in vitro. J Leukoc Biol 2003; 74:233-42; PMID:12885940; http://dx.doi.org/10.1189/jlb.0303097
   PubMedGoogle Scholar
• Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, Deng B, Johnson KA, Witek JS, Senices M, Konz RF et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002; 16:559-69; PMID:11970879; http://dx.doi.org/10.1016/S1074-7613(02)00295-9
   PubMed Web of Science ®Google Scholar
• Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004; 172:2048-58; PMID:14764669; http://dx.doi.org/10.4049/jimmunol.172.4.2048
   PubMed Web of Science ®Google Scholar
• Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE, 3rd. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006; 177:120-9; PMID:16785506; http://dx.doi.org/10.4049/jimmunol.177.1.120
   PubMed Web of Science ®Google Scholar
• Hashmi MH, Van Veldhuizen PJ. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsedrefractory indolent non-Hodgkin's lymphoma. Exp Opin Biol Ther 2010; 10:807-17; PMID:20384523; http://dx.doi.org/10.1517/14712598.2010.480971
   PubMed Web of Science ®Google Scholar
• Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009; 15:2123-9; PMID:19276257; http://dx.doi.org/10.1158/1078-0432.CCR-08-2663
   PubMed Web of Science ®Google Scholar
• Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 2007; 13:3630-6; PMID:17575227; http://dx.doi.org/10.1158/1078-0432.CCR-07-0410
   PubMed Web of Science ®Google Scholar
• Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 2008; 26:2034-9; PMID:18347008; http://dx.doi.org/10.1200/JCO.2007.14.5193
   PubMed Web of Science ®Google Scholar
• Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003; 102:4090-8; PMID:12893770; http://dx.doi.org/10.1182/blood-2003-03-0669
   PubMed Web of Science ®Google Scholar
• Wan CK, Oh J, Li P, West EE, Wong EA, Andraski AB, Spolski R, Yu ZX, He J, Kelsall BL et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013; 38:514-27; PMID:23453633; http://dx.doi.org/10.1016/j.immuni.2013.02.011
   PubMed Web of Science ®Google Scholar
• Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33:35-41; PMID:22032984; http://dx.doi.org/10.1016/j.tips.2011.09.004
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771-80; PMID:10704459; http://dx.doi.org/10.1084/jem.191.5.771
   PubMed Web of Science ®Google Scholar
• Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, Anderson D, Eisenmann J, Grabstein K, Caligiuri MA. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180:1395-403; PMID:7523571; http://dx.doi.org/10.1084/jem.180.4.1395
   PubMed Web of Science ®Google Scholar
• Gordy LE, Bezbradica JS, Flyak AI, Spencer CT, Dunkle A, Sun J, Stanic AK, Boothby MR, He YW, Zhao Z et al. IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol 2011; 187:6335-45; PMID:22084435; http://dx.doi.org/10.4049/jimmunol.1003965
   PubMed Web of Science ®Google Scholar
• Lu J, Giuntoli RL, 2nd, Omiya R, Kobayashi H, Kennedy R, Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res 2002; 8:3877-84; PMID:12473603
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med 2009; 7:109; PMID:20021667; http://dx.doi.org/10.1186/1479-5876-7-109
   PubMed Web of Science ®Google Scholar
• Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, Riddell SR. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114:2417-26; PMID:19605850; http://dx.doi.org/10.1182/blood-2008-12-189266
   PubMed Web of Science ®Google Scholar
• Kanegane H, Tosato G. Activation of naive and memory T cells by interleukin-15. Blood 1996; 88:230-5; PMID:8704178; http://dx.doi.org/10.1073/pnas.0902637106
   PubMed Web of Science ®Google Scholar
• Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A 2009; 106:7513-8; PMID:19383782; http://dx.doi.org/10.1073/pnas.0902637106
   PubMed Web of Science ®Google Scholar
• Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 16:6019-28; PMID:20924130; http://dx.doi.org/10.1158/1078-0432.CCR-10-1966
   PubMed Web of Science ®Google Scholar
• Ochoa MC, Mazzolini G, Hervas-Stubbs S, de Sanmamed MF, Berraondo P, Melero I. Interleukin-15 in gene therapy of cancer. Curr Gene Ther 2013; 13:15-30; PMID:23157547; http://dx.doi.org/10.2174/156652313804806561
   PubMed Web of Science ®Google Scholar
• Elhage O, Galustian C, Ukimura O, Gill I, Smith R, Dasgupta P. 1789 Selection of optimal cytokine combinations for immunotherapy of prostate cancer. J Urol 2011; 185:e719; PMID:15843522; http://dx.doi.org/10.1016/j.juro.2011.02.2139
   Google Scholar
• Kawauchi K, Ihjima K, Yamada O. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinaseAkt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 2005; 174:5261-9; PMID:15843522; http://dx.doi.org/10.4049/jimmunol.174.9.5261
   PubMed Web of Science ®Google Scholar
• Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 2012; 7:e30264; PMID:22279576; http://dx.doi.org/10.1371/journal.pone.0030264
   PubMed Web of Science ®Google Scholar
• Li Y, Zhi W, Wareski P, Weng NP. IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro. J Immunol 2005; 174:4019-24; PMID:15778359; http://dx.doi.org/10.4049/jimmunol.174.7.4019
   PubMedGoogle Scholar
• Hsu C, Jones SA, Cohen CJ, Zheng Z, Kerstann K, Zhou J, Robbins PF, Peng PD, Shen X, Gomes TJ et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109:5168-77; PMID:17353346; http://dx.doi.org/10.1182/blood-2006-06-029173
   PubMed Web of Science ®Google Scholar
• Wallace DL, Berard M, Soares MV, Oldham J, Cook JE, Akbar AN, Tough DF, Beverley PC. Prolonged exposure of naive CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology 2006; 119:243-53; PMID:17005004; http://dx.doi.org/10.1111/j.1365-2567.2006.02429.x
   PubMed Web of Science ®Google Scholar
• Yamada O, Ozaki K, Akiyama M, Kawauchi K. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells. Mol Cancer Ther 2012; 11:1112-21; PMID:22402124; http://dx.doi.org/10.1158/1535-7163.MCT-11-0850
   PubMed Web of Science ®Google Scholar
• Konnikova L, Simeone MC, Kruger MM, Kotecki M, Cochran BH. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res 2005; 65:6516-20; PMID:16061629; http://dx.doi.org/10.1158/0008-5472.CAN-05-0924
   PubMed Web of Science ®Google Scholar
• Frolkis M, Fischer MB, Wang Z, Lebkowski JS, Chiu CP, Majumdar AS. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther 2003; 10:239-49; PMID:12637945; http://dx.doi.org/10.1038/sj.cgt.7700563
   PubMed Web of Science ®Google Scholar
• Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174:3798-807; PMID:15749921; http://dx.doi.org/10.4049/jimmunol.174.6.3798
   PubMed Web of Science ®Google Scholar
• Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002; 100:3633-8; PMID:12393617; http://dx.doi.org/10.1182/blood-2001-12-0293
   PubMed Web of Science ®Google Scholar
• Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003; 101:4887-93; PMID:12586624; http://dx.doi.org/10.1182/blood-2002-11-3392
   PubMed Web of Science ®Google Scholar
• Brunner S, Herndler-Brandstetter D, Arnold CR, Wiegers GJ, Villunger A, Hackl M, Grillari J, Moreno-Villanueva M, Bürkle A, Grubeck-Loebenstein B. Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8+ T cells sensitizing them to apoptotic cell death. Aging Cell 2012; 11:579-87; PMID:22435726; http://dx.doi.org/10.1111/j.1474-9726.2012.00819.x
   PubMedGoogle Scholar
• Armant M, Delespesse G, Sarfati M. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. Immunology 1995; 85:331-7; PMID:7642225; http://dx.doi.org/doi:10.1016/j.molimm.2006.04.029
   PubMed Web of Science ®Google Scholar
• Bosque A, Marzo I, Naval J, Anel A. Apoptosis by IL-2 deprivation in human CD8+ T cell blasts predominates over death receptor ligation, requires Bim expression and is associated with Mcl-1 loss. Mol Immunol 2007; 44:1446-53; PMID:16806475; http://dx.doi.org/10.1016/j.molimm.2006.04.029
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA, Morre M et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009; 15:528-36; PMID:19396174; http://dx.doi.org/10.1038/nm.1953
   PubMed Web of Science ®Google Scholar
• Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, Osborne DF, Clark AT, Coopersmith CM, McDunn JE et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010; 184:1401-9; PMID:20026737; http://dx.doi.org/10.4049/jimmunol.0902307
   PubMed Web of Science ®Google Scholar
• Barker BR, Parvani JG, Meyer D, Hey AS, Skak K, Letvin NL. IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes. J Immunol 2007; 179:3596-603; PMID:17785794; http://dx.doi.org/10.4049/jimmunol.179.6.3596
   PubMed Web of Science ®Google Scholar
• Dure M, Macian F. IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol Immunol 2009; 46:999-1006; PMID:18990450; http://dx.doi.org/10.1016/j.molimm.2008.09.029
   PubMedGoogle Scholar
• Chikuma S, Terawaki S, Hayashi T, Nabeshima R, Yoshida T, Shibayama S, Okazaki T, Honjo T. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol 2009; 182:6682-9; PMID:19454662; http://dx.doi.org/10.4049/jimmunol.0900080
   PubMed Web of Science ®Google Scholar
• Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C, Bordignon C, Bonini C. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2002; 101:1290-8; PMID:12393508; http://dx.doi.org/10.1182/blood-2002-08-2351
   PubMedGoogle Scholar
• Griffioen M, van Egmond EHM, Kester MGD, Willemze R, Falkenburg JHF, Heemskerk MHM. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica 2009; 94:1316-20; PMID:19734426; http://dx.doi.org/10.3324/haematol.2008.001677
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011; 365:1673-83; PMID:22047558; http://dx.doi.org/10.1056/NEJMoa1106152
   PubMed Web of Science ®Google Scholar